The IPCAVD Program Coordination and Product Development Core (CoreA) will serve as the primary coordinating center for the integration and advancement of all Projects and Cores; provide biostatistical support for IPCAVD research programs; and have primary responsibility for interacting with NIH program staff and our External Steering Committee to ensure that IPCAVD timelines and milestones are accomplished as responsibly and expeditiously as possible. Core A will be responsible for interactions with our collaborating vaccine manufacturer, Bavarian Nordic, as well as with our collaborating consultants at SRI International who will conduct the majority of our pre-clinical vaccine safety studies. With the assistance of SRI International, Core A will work to ensure effective preparation and timely processing and filing of FDA Investigational New Drug (IND) applications in support of the improved MVA-HIV vaccines to be studied in our proposed Phase I clinical trial. Core Astaff will coordinate the pro-clinical macaque immunogenicity studies to be conducted at the Yerkes Primate Research Center in support of our IND filings. We intend to simultaneously manufacture 2 different MVA vaccine candidates and simultaneously file 2 separate IND applications to enable conduct of a comparative Phase I trial in healthy volunteers. Core A staff will be also responsible for ensuring that all IPCAVD studies are performed in accordance with all prevailing regulations for the conduct of responsible and ethical research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI061728-01
Application #
6844243
Study Section
Special Emphasis Panel (ZAI1-EC-A (M3))
Project Start
2004-07-01
Project End
2009-06-30
Budget Start
2004-09-02
Budget End
2005-08-31
Support Year
1
Fiscal Year
2004
Total Cost
$2,140,692
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Petravic, Janka; Vanderford, Thomas H; Silvestri, Guido et al. (2013) Estimating the contribution of the gut to plasma viral load in early SIV infection. Retrovirology 10:105
Garber, David A; O'Mara, Leigh A; Gangadhara, Sailaja et al. (2012) Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 86:12605-15
Vanderford, Thomas H; Bleckwehl, Chelsea; Engram, Jessica C et al. (2011) Viral CTL escape mutants are generated in lymph nodes and subsequently become fixed in plasma and rectal mucosa during acute SIV infection of macaques. PLoS Pathog 7:e1002048
Engram, Jessica C; Dunham, Richard M; Makedonas, George et al. (2009) Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J Immunol 183:706-17
Chavan, R; Marfatia, K A; An, I C et al. (2006) Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. J Virol 80:7676-87
Chahroudi, Ann; Garber, David A; Reeves, Patrick et al. (2006) Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J Virol 80:8469-81
Chahroudi, Ann; Chavan, Rahul; Kozyr, Natalia et al. (2005) Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol 79:10397-407